
Our companion SS-31 sequence article explains the four residues and their stereochemistry; this article focuses on cardiolipin binding and its membrane consequences. SS-31 (elamipretide) interacts with cardiolipin through two linked contacts: electrostatic attraction of positively charged peptide groups to anionic phosphate headgroups, and hydrophobic insertion of aromatic groups toward the membrane’s acyl-chain region.[1][2] These contacts help explain why a small peptide can influence both membrane organization and the proteins that depend on it.
The Molecular Contact: Anchoring, Then Burial

SS-31’s aromatic-cationic motif brings together two different chemical preferences. Basic, positively charged groups favor interactions with negatively charged lipid phosphates, while aromatic groups can partition into the nonpolar membrane interior. This amphipathic arrangement allows contact with both the aqueous environment and the lipid bilayer.[3] The mechanism depends on that combination, rather than on positive charge alone.
All-atom molecular dynamics simulations describe an approach state, in which cationic groups anchor near lipid phosphates, and a burial state, in which aromatic groups enter the nonpolar core. These are modeled interaction states, not direct observations of a fixed sequence of events in living mitochondria.[2] They provide a physical explanation for how initial attraction can develop into closer membrane association.
Experimental binding results complement this picture. NMR studies summarized in the same review report binding to inner-membrane-mimetic vesicles and isolated mitochondria that depends on cardiolipin. Binding and subsequent changes in membrane properties also depend on cardiolipin’s acyl chains.[2] The headgroup environment and the hydrophobic region therefore both matter; the interaction is not adequately described as a peptide simply sticking to a charged surface.
Nevertheless, electrostatic recruitment is broader than a lock-and-key recognition of cardiolipin. Membrane analyses indicate that interaction tracks surface charge more closely than lipid headgroup identity. Anionic headgroups create a local electric field that increases the peptide concentration near the bilayer and favors subsequent hydrophobic contacts.[2] This supports preferential association with cardiolipin-rich membranes, but acyl-chain dependence does not by itself establish exclusive recognition of cardiolipin over every other anionic lipid.
A proposed explanation for cell permeability is that aromatic-ring π electrons shield positive charges. This remains a suggested contribution to peptide behavior, rather than a demonstrated account of every step from the cell surface to the inner mitochondrial membrane.[3] Membrane binding and cellular entry are related questions, but evidence for one does not fully resolve the other.
Why Cardiolipin’s Location and Shape Matter

Cardiolipin is concentrated in the inner mitochondrial membrane, where it supports cristae formation and the organization of respiratory complexes into supercomplexes.[1] Its structure contains two phosphate groups and four acyl chains, unlike the two-chain architecture of many membrane phospholipids.[3] This places the peptide’s binding partner in the membrane system responsible for oxidative phosphorylation, rather than distributing its effects indiscriminately across cellular membranes.
Cristae are a relevant context because their folded architecture and respiratory organization depend on cardiolipin. Cardiolipin has negative intrinsic spontaneous curvature, and model membranes and molecular dynamics simulations show curvature-dependent partitioning; it also concentrates in high-curvature regions such as bacterial poles and nanotubes derived from giant unilamellar vesicles, although the specifics of its curvature behavior remain contentious.[4] The supplied evidence supports cardiolipin enrichment and curvature-dependent sorting in high-curvature membrane regions, but it has not directly measured preferential SS-31 accumulation at high-curvature cristae sites in intact mitochondria or tissue. The implication for SS-31 selectivity is that a positively charged peptide would be electrostatically concentrated at cardiolipin-enriched, high-curvature anionic membrane surfaces and then engage in hydrophobic contacts; preferential cristae enrichment remains an inference rather than a direct measurement in this evidence set.
Binding can also change membrane properties. In the membrane systems summarized in the mechanistic review, elamipretide reduces surface potential and dipole potential without changing transmembrane potential.[2] Thus, changing charge near the membrane interface is not equivalent to dissipating the electrical potential across the membrane. Conflating those measurements would obscure an important distinction in the proposed mechanism.
Two nonexclusive explanations have been proposed for the reduction in negative surface charge density: positive countercharges accumulate in the headgroup region, and basic peptide groups interact directly with lipid phosphates. Reported physical changes include increased cardiolipin self-association, reduced lateral lipid diffusivity and tighter lateral packing, without disruption of the lamellar bilayer.[2] Increased curvature and membrane surface area are proposed consequences of these changes. They offer a possible connection to cristae organization, but are not direct proof that SS-31 selectively occupies curved cristae ridges.
Downstream Effects: Cytochrome c, Cristae, Complexes, and Swelling
The cardiolipin–cytochrome c interaction connects lipid binding to protein function. Cytochrome c can act as an electron carrier or acquire peroxidase activity through its interaction with cardiolipin. The latter activity promotes cardiolipin peroxidation, which is associated with mitochondrial damage during ischemia.[1][5]
In the preclinical mechanistic work, the SS-31/cardiolipin complex inhibited cytochrome c peroxidase activity by protecting its heme iron. The broader mechanism is described as limiting the peroxidase switch while preserving electron-carrying function.[5][1] This is more specific than a general claim that SS-31 removes oxidants: it links membrane association to the behavior of a cardiolipin-associated protein.
Structural and energetic endpoints accompany this mechanism in animal models. In rats subjected to renal ischemia, SS-31 protected cristae membranes, prevented mitochondrial swelling and supported prompt ATP recovery during reperfusion.[5] In rat cardiac ischemia–reperfusion studies summarized in the 2025 mechanistic review, elamipretide mitigated loss of supercomplex coupling and fragmentation of cristae networks.[2] These findings concern rat injury models, not human outcomes.
A separate review describes enhanced activity of respiratory complexes I, III and IV through improved assembly and stability.[3] This is secondary-literature support for a respiratory-complex mechanism; it does not establish a universal magnitude of enhancement across preparations or tissues. Membrane organization, complex assembly and respiratory activity are connected endpoints, but they are not interchangeable measurements.
Mitochondrial permeability transition and swelling supply another functional link. In isolated mitochondria, the aromatic-basic SS peptide series inhibited permeability transition and swelling and prevented calcium-induced cytochrome c release. Analogs lacking dimethyltyrosine failed to inhibit mitochondrial ROS generation or swelling.[6] The abstract does not establish the same negative result for every other endpoint, so that comparison should not be extended to all peptide effects.
Dimethyltyrosine contributes radical-scavenging properties to this peptide series.[6] Consequently, the analog comparison does not isolate cardiolipin binding as the sole explanation for protection against swelling. It shows that the chemical motif matters, while leaving the relative contributions of membrane interaction and scavenging unresolved. Likewise, inhibition of permeability transition is a functional observation, not evidence that SS-31 directly binds a pore component.
What Each Experimental Level Can and Cannot Show
Model membranes and liposomes isolate the lipid contribution. They support cardiolipin-dependent binding, acyl-chain dependence and changes in bilayer electrostatics.[2] Simulations add an atomistic description of approach and burial, but neither simplified membranes nor simulations reproduce the full protein-rich environment of a living cell.
Isolated mitochondria retain organelle architecture and permit direct measurements of swelling, permeability transition and cytochrome c release. Binding has also been examined in these preparations.[2][6] These experiments connect molecular interaction with organelle behavior, but exclude the surrounding cellular environment.
Cell studies test whether effects persist in a cellular setting. In neuronal N(2)A cells, the SS peptide series reduced intracellular reactive oxygen species and cell death caused by t-butylhydroperoxide; the study also reported prevention of depolarization in cells exposed to 3-nitropropionic acid.[6] These cellular phenotypes do not identify the exact membrane contacts responsible for each outcome.
Animal models extend the question to tissue injury and organ-level consequences. Rat renal and cardiac ischemia models link SS-31 exposure with preservation of cristae or respiratory organization.[5][2] They provide biological context beyond isolated preparations, but do not establish human efficacy.
Human Status: One Accelerated Approval, Not an Efficacy Claim
On 19 September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg. The accelerated pathway carries a requirement for a confirmatory post-approval trial.[7] This is the regulatory status of a specific medicine and indication, not approval of research-grade SS-31 or evidence for other uses.
Where the Model Stops
Binding evidence does not yet provide every structural or quantitative answer. The primary study reporting high-affinity cardiolipin binding used a polarity-sensitive fluorescent analog of SS-31.[5] Numerical affinity values from that derivative should not automatically be assigned to the unlabeled peptide. Similarly, the approach-and-burial description is a simulation-derived model, not an experimentally resolved structure of a native membrane complex.[2]
The frequently repeated thousand-fold inner-membrane concentration was reported for the SS peptide series, rather than established separately for every SS-31 preparation or tissue.[6] The strongest mechanistic conclusion is therefore qualitative: electrostatic recruitment and hydrophobic association alter cardiolipin-containing membranes, with downstream protein and organelle effects demonstrated in preclinical systems. Exact native-membrane occupancy and curvature-specific enrichment remain unresolved.
Related research: What Is SS-31? Cardiolipin and Mitochondrial Function; SS-31 vs MOTS-c: Two Mitochondrial Research Approaches; SS-31.
Research Use Only. This article is for laboratory research and analytical education, not a validated experimental protocol or medical or veterinary advice. Research materials are not for administration to humans or animals, diagnosis or treatment.
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171:2029–2050.
- Sabbah HN, Alder NN, Sparagna GC, et al. Contemporary insights into elamipretide’s mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother. 2025;187:118056.
- Tung C, Varzideh F, Farroni E, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci. 2025;26:944.
- Setting the curve: the biophysical properties of lipids in mitochondrial form and function — review.
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250–1261.
- Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279:34682–34690.
- FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. September 19, 2025.